P‑glycoprotein inhibition increases the transport of dauricine across the blood‑brain barrier
- Authors:
- Pei‑Liang Dong
- Hua Han
- Tian‑Yu Zhang
- Bingyou Yang
- Qiu‑Hong Wang
- Gao‑Wa Eerdun
View Affiliations
Affiliations: Key Laboratory of Chinese Materia Medica of Ministry of Education, Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang 150040, P.R. China, Department of Pharmacology, The First Hospital of Hebei Medical University, Shijiazhuang, Hebei 050031, P.R. China
- Published online on: December 27, 2013 https://doi.org/10.3892/mmr.2013.1880
-
Pages:
985-988
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Abstract
Dauricine is the major bioactive component isolated from the roots of Menispermum dauricum D.C. The aim of the present study was to investigate the role of P‑glycoprotein in the transport of dauricine across the blood‑brain barrier by pre‑treatment with the P‑glycoprotein inhibitor verapamil. Sprague Dawley rats were divided into a verapamil group (pretreated with verapamil at a dose of 20 mg/kg) and a control group (pretreated with the same volume of normal saline). After 90 min, the animals were injected intravenously with dauricine (10 mg/kg). At 15, 30 and 60 min after dauricine administration, the levels of dauricine in the blood and brain were detected by high‑performance liquid chromatography. Compared with the control group, the dauricine concentration in the brains of the rats in the verapamil group was significantly increased. Furthermore, the brain‑plasma ratio of dauricine in the rats pretreated with verapamil was significantly higher than that of the animals in the control group. However, there was no difference identified between dauricine levels in the plasma of the verapamil and the control groups. The results indicated that dauricine is able to pass the blood‑brain barrier, and that P‑glycoprotein has an important role in the transportation of dauricine across the blood‑brain barrier.
View Figures |
Figure 1
|
 |
Figure 2
|
 |
Figure 3
|
 |
Figure 4
|
 |
Figure 5
|
 |
Figure 6
|
 |
Figure 7
|
View References
|
1
|
Abbott NJ, Patabendige AA, Dolman DE,
Yusof SR and Begley DJ: Structure and function of the blood-brain
barrier. Neurobiol Dis. 37:13–25. 2010. View Article : Google Scholar
|
|
2
|
Bellavance MA, Blanchette M and Fortin D:
Recent advances in blood-brain barrier disruption as a CNS delivery
strategy. AAPS J. 10:166–177. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mehdipour AR and Hamidi M: Brain drug
targeting: a computational approach for overcoming blood-brain
barrier. Drug Discov Today. 14:1030–1036. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
He L and Liu GQ: Interaction of multidrug
resistance reversal agents with P-glycoprotein ATPase activity on
blood-brain barrier. Acta Pharmacol Sin. 23:423–429.
2002.PubMed/NCBI
|
|
5
|
Liu JY, Thom M, Catarino CB, Martinian L,
Figarella-Branger D, Bartolomei F, Koepp M and Sisodiya SM:
Neuropathology of the blood-brain barrier and pharmaco-resistance
in human epilepsy. Brain. 135:3115–3133. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Pérez-Tomás R: Multidrug resistance:
retrospect and prospects in anti-cancer drug treatment. Curr Med
Chem. 13:1859–1876. 2006.PubMed/NCBI
|
|
7
|
Qian JQ: Cardiovascular pharmacological
effects of bisbenzylisoquinoline alkaloid derivatives. Acta
Pharmacol Sin. 23:1086–1092. 2002.PubMed/NCBI
|
|
8
|
Xia JS, Li Z, Dong JW, Tu H and Zeng FD:
Dauricine-induced changes in monophasic action potentials and
effective refractory period of rabbit left ventricle in situ. Acta
Pharmacol Sin. 23:371–375. 2002.PubMed/NCBI
|
|
9
|
Tang XD, Zhou X and Zhou KY: Dauricine
inhibits insulin-like growth factor-I-induced hypoxia inducible
factor 1alpha protein accumulation and vascular endothelial growth
factor expression in human breast cancer cells. Acta Pharmacol Sin.
30:605–616. 2009. View Article : Google Scholar
|
|
10
|
Yang Z, Li C, Wang X, et al: Dauricine
induces apoptosis, inhibits proliferation and invasion through
inhibiting NF-kappaB signaling pathway in colon cancer cells. J
Cell Physiol. 225:266–275. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Li YH and Gong PL: Neuroprotective effects
of dauricine against apoptosis induced by transient focal cerebral
ischaemia in rats via a mitochondrial pathway. Clin Exp Pharmacol
Physiol. 34:177–184. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Begley DJ: Delivery of therapeutic agents
to the central nervous system: the problems and the possibilities.
Pharmacol Ther. 104:29–45. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Megard I, Garrigues A, Orlowski S, et al:
A co-culture-based model of human blood-brain barrier: application
to active transport of indinavir and in vivo-in vitro correlation.
Brain Res. 927:153–167. 2002. View Article : Google Scholar : PubMed/NCBI
|
